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Chemokines are a class of small heparin-binding mole-
cules which orchestrate the infiltration of leukocyte
subsets into the liver during acute and chronic injury.
In experimental models of liver fibrosis, chemokines
are secreted by liver resident (e.g. hepatocytes, stellate
cells) and liver infiltrating cells (e.g. leukocytes, plate-
lets). Chemokines bind to characteristic G-protein
coupled transmembraneous receptors which are also
widely distributed within the liver.
Although the chemokine system has long been consid-
ered as having a high degree of redundancy, a number
of important effects of specific chemokines and their
receptors have been discovered within the last years.
Notably, important chemokine effects beyond immune
cells recruitment have also been identified.
In human hepatitis C induced liver disease, the chemo-
kine receptors CXCR3 and CCR5 are highly expressed on
liver resident cells and on infiltrating lymphocytes. Both
receptors have also been functionally studied in experi-
mental models of liver injury.
CXCR3 binds the CXC chemokines CXCL9, CXCL10
and CXCL11. In a quantitative trait locus analysis in mice,
these chemokines were shown to be located within a fibro-
sis associated haplotype block. Functional investigation of
CXCL9 showed that this chemokine is secreted by hepato-
cytes and can bind to hepatic stellate cells through its
receptor CXCR3. However, in contrast to most other che-
mokines, CXCL9 does not stimulate stellate cells, but
represses the secretion and mRNA expression of collagen.
As stellate cells are the pivotal collagen-producing cell
types during liver fibrogenesis, these results implied anti-
fibrotic properties of CXCL9. Indeed, mice lacking the
CXCR3 receptor display pronounced liver fibrosis com-
pared to their wild-type littermates after challenge with
the hepatotoxins CCl4 and thioacetamide. In humans, a
splice variant of CXCR3 can also bind the platelet-derived
chemokine CXCL4. In contrast, the specific receptor for
CXCL4 has not yet been identified in mice. However,
CXCL4 can interact with other chemokines (e.g. CCL5)
and thereby modulate their effects on target cells. In vivo,
mice lacking CXCL4 are significantly protected from
severe liver fibrosis, demonstrating that important effects
of CXCL4 in mice are indeed mediated by other receptors
than CXCR3. Amelioration of liver fibrosis in CXCL4
knockout mice is associated with lower pro-inflammatory
chemokine levels (e.g. CCL5 and CXCL1) and a reduced
infiltration of T-cells and neutrophils into the liver.
A similar reduction in infiltrating T-cells is observed in
mice lacking the T-cell chemoattractant CCL5, which
form heterodimers with CXCL4. In these mice, fibrosis is
also greatly reduced in chronic damage models, which is
in line with earlier findings about a pivotal role of the
CCL5 receptors CCR1 and CCR5 in liver fibrosis.
Taken together, these results imply that chemokines
play important, non-redundant roles during liver damage.
Pharmacologically, chemokines and their receptors are
amongst the best targetable molecules and the first che-
mokine receptor antagonists have already been licensed
for human use in infectious diseases (mainly HIV infec-
tion). Thus, the further elucidation of specific chemokine
pathways in liver diseases might lead to pre-clinical and
clinical studies to modulate liver injury in the near future.
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